{"url_path":"/sec/gyre/8-k/2026-07-15/cover-page","section_key":"cover-page","section_title":"Cover Page","topic":"sec","document":{"doc_type":"8-K/A","doc_date":"2026-07-15","source_url":"https://www.sec.gov/Archives/edgar/data/1124105/0001140361-26-028564-index.html","accession_number":"0001140361-26-028564","cik":"0001124105","ticker":"GYRE","issuer_name":"GYRE THERAPEUTICS, INC.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1124105/0001140361-26-028564-index.html","primary_entity_key":"0001124105","primary_entity_name":"GYRE THERAPEUTICS, INC."},"word_count":523,"has_tables":true,"body_markdown":"false0001124105NASDAQ00011241052026-05-042026-05-04\n\nUNITED STATES\n\nSECURITIES AND EXCHANGE COMMISSION\n\nWASHINGTON, D.C. 20549\n\nFORM 8-K/A\n\nAmendment No. 1\n\nCURRENT REPORT\n\nPursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934\n\nDate of report (Date of earliest event reported): May 4, 2026\n\nGyre Therapeutics, Inc.\n\n(Exact name of registrant as specified in its charter)\n\nDelaware\n\n000-51173\n\n56-2020050\n\n(State or other jurisdiction of incorporation)\n\n(Commission File Number)\n\n(IRS Employer Identification No.)\n\n12730 High Bluff Drive\n\nSuite 250\n\nSan Diego, CA\n\n \n\n92130\n\n(Address of principal executive offices)\n\n \n\n(Zip Code)\n\nRegistrant’s telephone number, including area code: (858) 284-0115\n\nN/A\n\n(Former name or former address, if changed since last report)\n\nCheck the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the\nfollowing provisions (see General Instruction A.2. below):\n\n☐\n\nWritten communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)\n\n☐\n\nSoliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)\n\n☐\n\nPre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))\n\n☐\n\nPre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))\n\nSecurities registered pursuant to Section 12(b) of the Act:\n\nTitle of each class\n\n \n\nTrading Symbol(s)\n\n \n\nName of each exchange on which\n\nregistered\n\nCommon Stock\n\n \n\nGYRE\n\n \n\nThe Nasdaq Capital Market\n\nIndicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter)\nor Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).\n\nEmerging growth company ☐\n\nIf an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or\nrevised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐\n\nINTRODUCTORY NOTE\n\nThis Amendment No. 1 on Form 8-K/A (“Amendment No. 1”) amends the Current Report on Form 8-K of Gyre Therapeutics, Inc., a Delaware corporation (the “Company” or “Gyre”),\nfiled on May 4, 2026 (the “Original Report”), in which the Company reported, among other events, the closing of the Merger (as defined in the Original Report) with Cullgen Inc., a Delaware corporation (“Cullgen”), on May 4, 2026 (the “Closing Date”).\n\nThis Amendment No. 1 includes (i) the financial statements of Cullgen as of and for the three months ended March 31, 2026 and the year ended December 31, 2025, and (ii) the\nunaudited pro forma condensed combined balance sheet of Gyre and Cullgen as of March 31, 2026 and the unaudited pro forma condensed combined statement of operations of Gyre and Cullgen for the three months ended March 31, 2026 and the year ended\nDecember 31, 2025 and the related notes.\n\nThis Amendment No. 1 does not amend any other item of the Original Report or purport to provide an update or a discussion of any developments at the Company or its\nsubsidiaries, including Cullgen, subsequent to the filing date of the Original Report. The information previously reported in or filed with the Original Report is hereby incorporated by reference to this Form 8-K/A."}